Part 1.Correlation Between P53 Mutation Patterns And Prognosis In Endometrial Cancer Part 2.Correlation Between HER2 Expression,p53 Status,and Prognosis In High-Grade Endometrial Cancer

Part 1.Correlation between p53 Mutation Patterns and Prognosis in Endometrial CancerBackground:Endometrial cancer is one of the most common malignancies in women.The Chinese version of the expert consensus on molecular testing for endometrial cancer(2021 edition)divides endometrial cancer into four subtypes using immunohistochemistry and molecular testing,among which the p53 mutation subtype has the worst prognosis.Currently,data on survival outcomes of patients with p53 mutation subtype with different mutation patterns are still limited.Therefore,this study employed a retrospective,single-center research method to examine the correlation between mutation patterns and prognosis in patients with p53 mutant endometrial cancer.Methods:The clinical data and pathological information of p53 mutant endometrial cancer patients in Cancer Hospital of the Chinese Academy of Medical Sciences between July 2011 and October 2020 were systematically reviewed.Patient general information and prognosis were collected.The progression-free survival(PFS)was evaluated using Kaplan-Meier survival curve analysis.Results:A total of 82 patients(follow-up deadline:July 2022)were included,with a median age of 60 years(range:37-83 years)and an average age of 59.56 years.Immunohistochemistry results revealed that 61 out of 82 cases(74%)of p53 mutant endometrial cancer patients exhibited the missense mutation phenotype,while 21 cases(26%)had the nonsense mutation phenotype.The 3-year PFS rate was 55.4%.Univariate analysis demonstrated no significant correlation between p53 mutation type and progression-free survival(P=0.35>0.05).Conclusion:This study concludes that there is no statistically significant correlation between different mutation patterns of p53 and prognosis in patients with p53 mutant endometrial cancer.Part 2.Correlation between HER2 Expression,p53 Status,and Prognosis in High-Grade Endometrial CancerBackground:Endometrial cancer is one of the most common malignancies in women.The prognosis for high-grade endometrial cancer such as high-grade serous carcinoma,clear cell carcinoma and poor differentiated endometrioid carcinoma is relatively poor.Targeted therapy against HER2/ERBB2 has been developed and has shown significant efficacy in breast cancer and other cancers.However,the expression of HER2 in endometrial cancer patients varies greatly in different studies.This study aimed to analyze the HER2 expression rate,its correlation with p53 expression patterns,and prognosis in patients with high-grade endometrial cancer through a single-center retrospective analysis.Methods:Clinical data and pathological information of high-grade endometrial cancer patients who received treatment at the Cancer Hospital of the Chinese Academy of Medical Sciences from January 2011 to December 2020 were systematically reviewed.General patient information and prognostic outcomes were collected.Tissue wax blocks with typical tumor pathological features were selected for HER2 immunohistochemical staining and FISH gene detection.The chi-square test was used to analyze the correlation between HER2 and p53,while Kaplan-Meier survival curves and log-rank tests were employed to evaluate progression-free survival(PFS)and overall survival(OS).Results:A total of 95 patients were included in this study(follow-up deadline:April 2023),with a median age of 59 years(range:26-76 years)and an average age of 57.58 years.Based on p53 immunohistochemistry results,22 of the 95 high-grade endometrial cancer patients(23%)had a wild-type p53,while 72(76%)had a mutated p53(including nonsense mutations and missense mutations),and 1(1%)had an unknown p53 expression pattern.According to HER2 immunohistochemical results,67 patients(71%)were scored as 0,16(17%)were scored as 1+,8(8%)were scored as 2+,and 4(4%)were scored as 3+.FISH detection was carried out on cases with scores of 2+and 3+,with 90 cases(95%)showing no amplification and 5 cases(5%)showing HER2 amplification.The chi-square test showed that there was no statistically significant correlation between HER2 amplification status and p53 expression status(P>0.05).The 5-year PFS rate was 53%,and the 5-year OS rate was 74.7%.Univariate analysis showed that HER2 amplification status had no significant correlation with PFS or OS(P>0.05).Conclusion:This study showed that the HER2 amplification rate in high-grade endometrial cancer patients was 5%.There was no statistically significant correlation between HER2 and p53 expression patterns.HER2 amplification was not significantly correlated with PFS or OS.